Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imbruvica for Hospitalized COVID-19 Patients with Cancer
NCT04439006Phase 1Completed
- Start
- Oct 2020
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ibrutinib in coronavirus disease 2019 (COVID-19) (2 arms). Primary endpoints: Proportion of patients with diminished respiratory failure and death at 30 days and Death at 30 days. Started Oct 2020; status: completed.
02
Drugs
ibrutinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04439006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04439006.